Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status \< 2. * Histologically or cytologically confirmed diagnosis of a relapsed/refractory solid tumor * Patient meets at least 1 of the following criteria: * Disease progression despite standard therapies * No standard therapies are available or such therapies are not anticipated to result in a durable response * Standard therapies are considered unsuitable or have been refused * Life expectancy \> 12 weeks * Able to be hospitalized from 1 day prior to the initial dosing until day 15 of the dosing, and from day 27 until day 29 of the dosing Exclusion Criteria: * Patient exhibits persistent subjective and objective findings of toxicity ≥ Grade 2 (CTCAE v4.0-JCOG) from the previous cancer treatment with antitumor effect (except of alopecias) * Received previous treatment with antitumor effect within 21 days prior to the scheduled initial dosing * Patient had a major surgical procedure within 21 days prior to the scheduled initial dosing or a major surgical procedure scheduled during the course of the study * Use of an investigational drug or device within 21 days prior to the scheduled initial dosing * Use of blood transfusion or hematopoietic growth factors within 14 days prior to the scheduled initial dosing * A positive test for hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) * Known history of a positive test for human immunodeficiency virus (HIV) infection * Patient has central nervous system (CNS) or leptomeningeal involvement with clinical symptoms